Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells

Endocrine

Volumn 45, Issue 1, 2014, Pages 148-152

  Maggisano, V ^a   Puppin, C ^b   Celano, M ^a   D'Agostino, M ^a   Sponziello, M ^c   Micali, S ^d   Navarra, M ^e   Damante, G ^b   Filetti, S ^c   Russo, D ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Histone deacetylase inhibitors; Radioiodine; Rat Leydig cell tumor; Sodium iodide symporter

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; MESSENGER RNA; SODIUM IODIDE SYMPORTER; VALPROIC ACID; VORINOSTAT;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL COUNT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; LEYDIG CELL TUMOR; LONG TERM EXPOSURE; MALE; NIS GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTIS CARCINOMA; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; LEYDIG CELL TUMOR; MALE; RATS; SYMPORTERS; TESTICULAR NEOPLASMS; VALPROIC ACID;

EID: 84895904565     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9972-4     Document Type: Article

References (25)

1. A. Mai, L. Altucci, Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 41, 199-213 (2009)
2. P. Chi, C.D. Allis, G.G. Wang, Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10(7), 457-459 (2010)
3. D. Russo, G. Damante, C. Durante, E. Puxeddu, S. Filetti, Epigenetics of thyroid cancer and novel therapeutic targets. J. Mol. Endocrinol. 46(3), R73-R81 (2011)
4. A.L. Galrão, A.K. Sodré, R.Y. Camargo, C.U. Friguglietti, M.A. Kulcsar, E.U. Lima, G. Medeiros-Neto, I.G. Rubio, Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression. Endocrine 43(1), 225-229 (2013)
5. A. De La Vieja, O. Dohan, O. Levy, N. Carrasco, Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol. Rev. 80, 1083-1105 (2000)
6. M. Schlumberger, L. Lacroix, D. Russo, S. Filetti, J.M. Bidart, Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat. Clin. Pract. Endocrinol. Metab. 3, 260-269 (2007)
7. O. Dohan, A. De la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C.S. Ginter, N. Carrasco, The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev. 24, 48-77 (2003)
8. T. Kogai, G.A. Brent, The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol. Ther. 135, 355-370 (2012)
9. C. Puppin, N. Passon, J.M. Hershman, S. Filetti, S. Bulotta, M. Celano, D. Russo, G. Damante, Cooperative effects of SAHA and VPA on NIS gene expression and proliferation of thyroid cancer cells. J. Mol. Endocrinol. 48, 217-227 (2012)
10. M. D'Agostino, P. Voce, M. Celano, M. Sponziello, S. Moretti, V. Maggisano, A. Verrienti, C. Durante, S. Filetti, E. Puxeddu, D. Russo, Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22, 138-144 (2012)
11. M. Celano, S. Schenone, D. Cosco, M. Navarra, E. Puxeddu, L. Racanicchi, C. Brullo, E. Varano, S. Alcaro, E. Ferretti, G. Botta, S. Filetti, M. Fresta, M. Botta, D. Russo, Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr. Relat. Cancer 15, 499-510 (2008)
12. S.J. Weiss, N.J. Philp, E.F. Grollman, Iodine transport in a continuous line of cultured cells from rat thyroid. Endocrinology 114, 1090-1098 (1984)
13. E. Fröhlich, P. Brossart, R. Wahl, Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. Eur. J. Nucl. Med. Mol. Imaging 36(5), 780-790 (2009)
14. C. Hawkins, C. Miaskowski, Testicular cancer: a review. Oncol. Nurs. Forum 23, 1203-1211 (1996)
15. I.L. Wapnir, M. van de Rijn, K. Nowels, P.S. Amenta, K. Walton, K. Montgomery, R.S. Greco, O. Dohán, N. Carrasco, Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J. Clin. Endocrinol. Metab. 88, 1880-1888 (2003)
16. D. Russo, A. Scipioni, C. Durante, E. Ferretti, L. Gandini, V. Maggisano, D. Paoli, A. Verrienti, G. Costante, A. Lenzi, S. Filetti, Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. Endocrine 40, 35-40 (2011)
17. S. Micali, V. Maggisano, A. Cesinaro, M. Celano, A. Territo, B.L. Reggiani, M. Sponziello, M. Migaldi, M. Navarra, G. Bianchi, S. Filetti, D. Russo, Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas. J. Endocrinol. 216(2), 125-133 (2013)
18. M. Kitazono, R. Robbey, Z. Zhan, N.J. Sarlis, M.C. Skarulis, T. Aikou, S. Bates, T. Fojo, Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 86, 3430-3435 (2001)
19. F. Furuya, H. Shimura, H. Suzuki, K. Taki, K. Ohta, K. Haraguchi, T. Onaya, T. Endo, T. Kobayashi, Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145, 2865-2875 (2004)
20. C. Puppin, F. D'Aurizio, A.V. D'Elia, L. Cesaratto, G. Tell, D. Russo, S. Filetti, E. Ferretti, E. Tosi, T. Mattei, A. Pianta, L. Pellizzari, G. Damante, Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 146, 3967-3974 (2005)
21. M. Sponziello, A. Scipioni, C. Durante, A. Verrienti, M. Maranghi, L. Giacomelli, E. Ferretti, M. Celano, S. Filetti, D. Russo, Regulation of sodium/iodide symporter and lactoperoxidase expression in four human breast cancer cell lines. J. Endocrinol. Invest. 33, 2-6 (2010)
22. N. Batty, G.G. Malouf, J.P. Issa, Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 280, 192-200 (2009)
23. J. Chang, D.S. Varghese, M.C. Gillam, M.C. Gillam, M. Peyton, B. Modi, R.L. Schiltz, L. Girard, E.D. Martinez, Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br. J. Cancer 106, 116-125 (2012)
24. P.A. Marks, W.S. Xu, Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 107, 600-608 (2009)
25. D. Russo, C. Durante, S. Bulotta, C. Puppin, E. Puxeddu, S. Filetti, G. Damante, Targeting histone deacetylase in thyroid cancer. Expert Opin. Ther. Targets 17(2), 179-193 (2013)